Jpmorgan Chase & CO Design Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 19,277 shares of DSGN stock, worth $127,613. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,277
Previous 89,215
78.39%
Holding current value
$127,613
Previous $550,000
86.55%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding DSGN
# of Institutions
96Shares Held
33.6MCall Options Held
13KPut Options Held
0-
Sr One Capital Management, LP6.53MShares$43.2 Million7.89% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$27.9 Million1.83% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$15.3 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$12.9 Million0.35% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.81MShares$12 Million0.01% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $369M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...